LUXTURNA DIN 02505851
Health Canada record
| Active ingredient(s) | VORETIGENE NEPARVOVEC 5000000000000 VG |
|---|---|
| Dosage form | Solution |
| Route | Subretinal |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | S01XA27 VORETIGENE NEPARVOVEC |
| Original market date | 14-Mar-2022 |
| Current status date | 14-Mar-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Novartis Pharmaceuticals Canada Inc — licence 100273, currently licensed, last inspection rating C (2025-01-14).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 24429 | 2020-10-13 | New Drug Submission (NDS) |